| Biologic Therapy |
1 |
1 |
| CAR-T |
0 |
0.99 |
| Leukemia |
0 |
0.5 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.4 |
| Genomic Medicine |
0 |
0.37 |
| Child |
0 |
0.31 |
| Hospital |
0 |
0.31 |
| Toxicology |
0 |
0.31 |
| Blood |
0 |
0.28 |
| Lymphoma |
0 |
0.28 |
| B-Cell Lymphoma |
0 |
0.27 |
| Revenue and Practice Management |
0 |
0.27 |
| Cancer |
0 |
0.24 |
| Follicular Lymphoma |
0 |
0.23 |
| Mantle Cell Lymphoma |
0 |
0.23 |
| Patient Safety |
0 |
0.2 |
| Healthcare and Medical Technology |
0 |
0.18 |
| Acute Leukemia |
0 |
0.16 |
| Acute Lymphoblastic Leukemia |
0 |
0.15 |
| Clinical Research |
0 |
0.14 |
| Gene Therapy |
0 |
0.14 |
| Multiple Myeloma |
0 |
0.1 |
| Receptors |
0 |
0.1 |
| Genetics |
0 |
0.07 |
| Grant |
0 |
0.07 |
| Immunotherapy |
0 |
0.07 |
| Point-of-Care |
0 |
0.07 |
| Transplantation |
0 |
0.07 |
| Infectious Mononucleosis |
0 |
0.06 |
| Intensive Care Unit |
0 |
0.06 |